Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer

Cancer Investigation

Volumn 26, Issue 7, 2008, Pages 671-679

  Derin, Duygu ^a   Eralp, Yesim ^a   Ozluk, Yasemin ^a   Yavuz, Ekrem ^a   Guney, Nese ^a   Saip, Pinar ^a   Igci, Abdullah ^a   Ozmen, Vahit ^a   Kücücük, Seden ^a   Aslay, Isik ^a   Aydiner, Adnan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chemoresistance; Hormone receptor; MAPK; Negative breast cancer; Prognosis and response predictions; Triple negative

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SIGNAL TRANSDUCTION; STAINING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT FAILURE;

EID: 48349094564     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801891628     Document Type: Article

References (42)

1. Parl, F.F.; Schmidt, B.P.; Dupont, W.D.; Wagner, R.K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984, 54, 2237-2242.
2. Pichon, M.F.; Broet, P.; Magdelenat, H.; et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996, 73, 1545-1551.
3. Sorlie, T.; Perou, C.M.; Tibshirani, R.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98, 10869-10874.
4. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10, 5367-5374.
5. Soutirou, C.; Neo, S.Y.; McShane, L.M.; et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100, 10393-10398.
6. Kim, M.J.; Ro, J.Y.R.; Ahn, S.H.; et al. Clinicopathlogic significance of the basal-like subtype of breast cancer: a comparison with hormone-receptor and Her-2/neu-overexpressing phenotypes. Hum Pathol 2006, 37, 1217-1226.
7. Hafty, B.G.; Yang, Q.; Reiss, M.; et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24, 5652-5657.
8. Cleator, S.; Heller, W.; Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet 2007, 8, 235-244.
9. Trendall-Smith, N.J.; Peston, D.; Shousha S. Adenoid cycstic carcinoma of the breast:a tumor commonly devoid of oestrogen receptors and related proteins. Histopathology 1999, 35, 241-248.
10. Rosen, P.P.; Cranor ML. Secretory carcinoma of the breast Arch Pathol Lab Med 1991, 115, 141-144.
11. Santen, R.J.; Song, R.X.; McPherson, R.; et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Ster Biochem Mol Biol 2002, 80, 239-256.
12. Small, G.W.; Shi, Y.Y.; Higgins, L.S.; Orlowski RZ. Mitogen-activated protein (MAP) kinase Phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007, 67, 4459-4466.
13. Denhardt DT. Signal transduction protein phosphorilation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. Biochem J 1996, 318, 729-747.
14. Neve, R.M.; Holbro, T.; Hynes NE. Distinct roles for phosphoinositide 3-kinase, mtogen-activated protein-kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002, 21, 4567-4576.
15. Eralp, Y.; Derin, D.; Ozluk, Y.; et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 2007; doi: 10.1093/annonc/mdm522.
16. Rakha, E.A.; El-Sayed, M.E.; Green, A.R.; et al. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25-32.
17. Gullick, W.J.; Love, S.B.; Wright, C.; et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991, 63, 434-438.
18. Paik, S.; Hazan, R.; Fisher, E.R.; et al. Pathologic findings from the National Surgical Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8, 103-112.
19. Press, M.F.; Bernstein, L.; Thomas, P.A.; et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15(8), 2894-2904.
20. Riou, G.; Mathieu, M.C.; Barrois, M.; et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001, 95(4), 266-270.
21. Ross, J.S.; Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998, 16(6), 413-428.
22. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19, 403-410.
23. Henson, D.E.; Ries, L.; Freedman, L.S.; Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991, 68, 2142-2149.
24. Schumacher, M.; Schmoor, C.; Sauerbrei, W.; et al. The prognostic value for histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993, 25, 235-245.
25. Reed, W.; Hannisdal, E.; Boehler, P.J.; et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow up of 14 to 30 years. Cancer 2000, 88, 804-813.
26. Jeng, M.H.; Shupnik, M.A.; Bender, T.P.; et al. Estrogen receptor expression and function in kong-term estrogen deprived human breast cancer cells. Endocrinology 1998, 139, 4164-4174.
27. Shim, W.S.; Conaway, M.; Masamura, S.; et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen-deprived human breast cancer cells in vivo. Endocrinology 2000, 141, 396-405.
28. Salh, B.; Marotta, C.; Mattewson, C.; et al. Investigation of the MEKMAP kinase-Rsk pathway in human breast cancer. Anticancer Res 1999, 19, 731-740.
29. Moyano, J.V.; Evans, J.R.; Chen, F.; et al. Alpha-B-crytallin is a novel onco-protein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006, 116, 261-270.
30. Esteva, F.J.; Hortobagyi, G.N.; Sahin, A.A.; et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using immunohistochemistry. Pathol Oncol Res 2001, 7, 171-177.
31. Esteva, F.J.; Sahin, A.A.; Smith, T.L.; et al. Prognostic significance of phosphorilated P38 mitogen-activated protein kinase and Her-2 expression in lymph node-positive breast carcinoma. Cancer 2004, 100, 499-506.
32. Oh, A.S.; Lorant, L.A.; Holloway, J.N.; et al. Hyperactivation of MAPK induces loss of Eralpha expression in breast cancer cells. Molec Endocrinol 2001, 15, 1344-1359.
33. Lu, C.; Speers, C.; Zhang, Y.; et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen-receptor-negative mammary tumors. J Natl Cancer Inst 2003, 95, 1825-1833.
34. Creighton, C.J.; Hilger, A.M.; Murthy, S.; et al. Activation of mitogen-activated protein (MAP) kinase in estrogen recetor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor negative human breast tumors. Cancer Res 2006, 66, 3903-3911.
35. Gutierrez, C.M.; Detre, S.; Johnston, S.; et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, Her-2, and p38 mitogen activated protein kinase. J Clin Oncol 2005, 23, 2469-2476.
36. Gee, J.M.W.; Robertson, J.F.R.; Ellis, I.O.; Nicholson RI. Phosphorilation of ERK1/2 mitogen-activated protein (MAP) kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001, 95, 247-254.
37. Mueller, H.; Flury, N.; Eppenberger-Castori, S.; et al. Potential prognostic value of mitogen-activated protein (MAP) kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000, 89, 384-388.
38. von Lintig, F.C.; Dreilinger, A.D.; Varki, N.M.; et al. Ras activation in human breast cancer. Breast Can Res Treat 2000, 62, 51-62.
39. McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul 2006, 46, 249-279.
40. Kauffmann-Zeh, A.; Rodriguez-Viciana, P.; Ulrich, E.; etal. Suppression of c-Myc induced apoptosis by Ras signalling through PI3K and PKB. Nature 1997, 385, 544-548.
41. Pearson, G.; Robinson, F.; Beers, G.T.; et al. Mitogen-activated protein-kinase pathways:regulation and physiological functions. Endocrine Rev 2001, 22, 153-183.
42. Davis, H.; Bignell, G.R.; Cox, C.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.